Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Current Leases (2019 - 2025)

Viking Therapeutics' Current Leases history spans 7 years, with the latest figure at $468000.0 for Q2 2025.

  • For Q2 2025, Current Leases changed N/A year-over-year to $468000.0; the TTM value through Jun 2025 reached $468000.0, changed N/A, while the annual FY2024 figure was $489000.0, 50.93% up from the prior year.
  • Current Leases for Q2 2025 was $468000.0 at Viking Therapeutics, down from $489000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $489000.0 in Q4 2024 and bottomed at $29000.0 in Q4 2021.
  • The 5-year median for Current Leases is $271000.0 (2022), against an average of $264625.0.
  • The largest annual shift saw Current Leases crashed 91.21% in 2021 before it surged 948.28% in 2022.
  • A 5-year view of Current Leases shows it stood at $29000.0 in 2021, then soared by 948.28% to $304000.0 in 2022, then increased by 6.58% to $324000.0 in 2023, then soared by 50.93% to $489000.0 in 2024, then dropped by 4.29% to $468000.0 in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Current Leases are $468000.0 (Q2 2025), $489000.0 (Q4 2024), and $324000.0 (Q4 2023).